Evidence map›Paper›PMID 32951157›Full record

Trial reportJournal of autism and developmental disorders2021

Visual Preference for Biological Motion in Children and Adults with Autism Spectrum Disorder: An Eye-Tracking Study.

Dzmitry A Kaliukhovich, Nikolay V Manyakov, Abigail Bangerter, Seth Ness, Andrew Skalkin, Matthew Boice, Matthew S Goodwin, Geraldine Dawson, Robert Hendren, Bennett Leventhal and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of autism and developmental disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dzmitry A KaliukhovichJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. dkaliukh@its.jnj.com.ORCID http://orcid.org/0000-0002-7476-5730
Nikolay V ManyakovJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium.
Abigail BangerterJanssen Research & Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.
Seth NessJanssen Research & Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.
Andrew SkalkinJanssen Research & Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.
Matthew BoiceJanssen Research & Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.
Matthew S GoodwinDepartment of Health Sciences, Bouvé College of Health Sciences, Northeastern University, 312E Robinson Hall, 360 Huntington Avenue, Boston, MA, 02115, USA.
Geraldine DawsonDuke Center for Autism and Brain Development, Duke University School of Medicine, 2608 Erwin Road, Suite 30, Durham, NC, 27705, USA.
Robert HendrenCenter for Child Health, Behavior and Development, Seattle Children's Research Institute, Department of Pediatrics, University of Washington School of Medicine, 2001 8th Ave Suite #400, Seattle, WA, 98121, USA.
Bennett LeventhalBenioff Children's Hospital, University of California, San Francisco, 401 Parnassus Ave, Langley Porter, San Francisco, CA, 94143-0984, USA.
Frederick ShicCenter for Child Health, Behavior and Development, Seattle Children's Research Institute, Department of Pediatrics, University of Washington School of Medicine, 2001 8th Ave Suite #400, Seattle, WA, 98121, USA.
Gahan PandinaJanssen Research & Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.

Funding

Mechanisms of Brain Dysmorphology in MN1 C-Terminal Truncation Syndrome, a Novel Intellectual Developmental Disability Disorder P50HD103524 · NICHD · UNIVERSITY OF WASHINGTON · PI DANIEL DOHERTY · 2020 to 2026
$9.9M
NICHD NIH HHS P50 HD103524
6 · The paper itself

Abstract

Participants with autism spectrum disorder (ASD) (n = 121, mean [SD] age: 14.6 [8.0] years) and typically developing (TD) controls (n = 40, 16.4 [13.3] years) were presented with a series of videos representing biological motion on one side of a computer monitor screen and non-biological motion on the other, while their eye movements were recorded. As predicted, participants with ASD spent less overall time looking at presented stimuli than TD participants (P < 10

Indexed as

Eye MovementsMotion PerceptionAdolescentAdultAttentionAutism Spectrum DisorderChildEye-Tracking TechnologyFemaleFixation, OcularHumansMaleMiddle AgedPhotic StimulationProspective StudiesTask Performance and AnalysisAutism spectrum disorderBiological motionBiomarkersEye-tracking

Identifiers

PMID32951157
PMCPMC8189980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.